Pharmaceuticals

A novel membrane technology promises to speed up production of next-gen medicines by solving a critical, energy-intensive bottleneck in pharmaceutical manufacturing.

ZOIA and Meta Healthcare's alliance brings a ready-to-use liquid nutrition to the US, promising to ease the daily burden for those with a rare metabolic disorder.

Positive Phase 3b data for Otsuka's centanafadine could revolutionize treatment for millions battling both ADHD and anxiety with a single, first-in-class drug.

Vaxart’s COVID pill vaccine trial sees funding cut, yet new funds for data analysis signal a complex bet by BARDA on the future of pandemic response.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

Professor Jason Chin’s Heinrich Wieland Prize signals a new era. His work in synthetic biology is enabling Constructive Bio to forge a new class of drugs.

A landmark survey reveals a stunning bipartisan mandate on reproductive health, showing a vast majority of Republican voters support protecting access to EC.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

Tiziana Life Sciences has dosed the final patient in a key trial for its nasal MS drug, foralumab. With data imminent, this could be a breakthrough for an untreatable form of the disease.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Oblenio Bio's oversubscribed Series B will advance a novel tri-specific T-cell engager, aiming to reset the immune system without harsh side effects.

ProQR Therapeutics secures a crucial $59.2M, extending its runway and gaining a powerful endorsement from partner Eli Lilly for its Axiomer RNA editing platform.

A new CMS program offers seniors blockbuster obesity drugs for $50. But this temporary fix raises profound questions about cost, access, and our healthcare future.

Insmed and EMBARC's 3,000-patient study of brensocatib aims to do more than treat a chronic lung disease—it aims to fundamentally alter its course.

Transgene unveils a scalable mpox vaccine using its cancer immunotherapy tech. Can this strategic pivot disrupt the market and fix global supply gaps?

A new license for C-Ray Therapeutics is more than a permit; it's a key move in Beijing's strategy to dominate the high-stakes radiopharmaceutical market.

ARS Pharmaceuticals' needle-free allergy spray, neffy, faces a major setback with commercial insurers, forcing a strategic pivot toward fiscal discipline.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.